Neuraminidase inhibitor

Zanamivir structure

Error creating thumbnail:

Oseltamivir

Error creating thumbnail:

Peramivir

Error creating thumbnail:

Laninamivir

Neuraminidase inhibitors are a class of antiviral drugs that block the neuraminidase enzyme. They are commonly used to prevent and treat influenza in both adults and children. Neuraminidase, an enzyme found on the surface of the influenza virus, is critical for the virus's replication and spread within the host organism. By inhibiting this enzyme, neuraminidase inhibitors interfere with the virus's ability to proliferate.

Mechanism of Action

Neuraminidase inhibitors work by binding to the active site of the neuraminidase enzyme. This prevents the enzyme from cleaving sialic acid residues on the surface of the host cells and newly formed viral particles. As a result, the release of new viruses from infected cells is inhibited, viral replication is halted, and the spread of the virus within the body is limited.

Types of Neuraminidase Inhibitors

There are several neuraminidase inhibitors available on the market, including:

• Oseltamivir (marketed under the brand name Tamiflu)
• Zanamivir (marketed under the brand name Relenza)
• Peramivir (marketed under the brand name Rapivab)
• Laninamivir (marketed under the brand name Inavir, available in Japan)

Each of these drugs has its own specific usage guidelines, routes of administration, and spectrum of activity against different strains of the influenza virus.

Clinical Use

Neuraminidase inhibitors are used for both the prevention and treatment of influenza. They are most effective when administered within 48 hours of the onset of symptoms. For prevention, they are used in situations where there is a high risk of influenza exposure, such as during outbreaks in closed communities. They can also be prescribed to individuals at high risk of influenza complications.

Resistance

Resistance to neuraminidase inhibitors can occur, and it is a growing concern. The influenza virus can mutate, leading to changes in the neuraminidase enzyme that reduce the effectiveness of these drugs. Monitoring for resistance patterns is an important aspect of public health efforts to control influenza.

Side Effects

The side effects of neuraminidase inhibitors are generally mild and can include nausea, vomiting, diarrhea, and headache. Rarely, more serious side effects such as allergic reactions or neuropsychiatric events may occur.

Conclusion

Neuraminidase inhibitors are a key tool in the management of influenza. They offer a means to mitigate the severity of the disease and reduce its spread, particularly during seasonal outbreaks and pandemics. Ongoing research and surveillance are essential to address the challenges of drug resistance and to develop new antiviral agents.